UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options and sold 9,500 shares of common stock on July 7, 2026 under a 10b5-1 plan.

On July 7, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold 9,500 shares of common stock in a series of open-market transactions at prices ranging from approximately $553.12 to $563.24 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The gross value of the option exercise, based on the reported market price of $135.42, is about $1.29 million, while the aggregate sale proceeds total roughly $5.3 million, resulting in a significant spread capture but overall representing a net disposition of shares rather than an increase in economic exposure. Following these transactions, Rothblatt held 40,513 shares of common stock directly, along with substantial indirect holdings through family trusts and a spouse, as well as additional stock options held in a family trust, indicating that despite the sizeable monetization, she continues to maintain a large overall equity position in United Therapeutics.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000093

Alert Tier

7